

- (51) International Patent Classification:

A61K 47/54 (2017.01) A61P 3/10 (2006.01)
- (21) International Application Number:

PCT/EP2024/055725
- (22) International Filing Date:

05 March 2024 (05.03.2024)
- (25) Filing Language:



English
- (26) Publication Language:

English
- (30) Priority Data:

23160259.0 06 March 2023 (06.03.2023) EP

23203738.2 16 October 2023 (16.10.2023) EP
- (71) Applicant: ASCENDIS PHARMA A/S [DK/DK]; Tuborg Boulevard 12, 2900 Hellerup (DK).
- (72) Inventors: SPROGØE, Kennett; c/o Ascendis Pharma A/S, Tuborg Boulevard 12, 2900 Hellerup (DK). BISEK, Nicola; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg (DE). WEISBROD, Samuel; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg (DE).
- (74) Agent: BÜCHEL, Edwin; Patentanwälte Isenbruck Bösl Hörschler PartG mbB, Seckenheimer Landstraße 4, 68163 Mannheim (DE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: DRUG COMPOUNDS COMPRISING ALBUMIN-BINDING MOIETIES



(57) Abstract: The present invention relates to compounds or a pharmaceutically acceptable salt thereof of formula (Ia) or (Ib) wherein each -D- is independently a drug moiety; each -AB¹ and -AB² is independently an albumin-binding moiety; each -L¹- is independently a linker moiety covalently and reversibly connected to -D-; each -L²- is independently a spacer or is absent; and x and y are an integer; to pharmaceutical compositions comprising at least one such compound and to their uses.